Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX

OBJECTIVES: Neoadjuvant therapy (NT) is used for advanced pancreatic ductal adenocarcinoma (PDAC). No clear guidelines exist for switching therapies when patients do not respond to initial NT. We sought to characterize patients who underwent early switch from FOLFIRINOX to gemcitabine/nab-paclitaxel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pancreas
Main Authors: Vreeland, Timothy J, McAllister, Florencia, Javadi, Sanaz, Prakash, Laura R., Fogelman, David R., Ho, Linus, Varadhachary, Gauri, Aloia, Thomas A., Vauthey, Jean-Nicolas, Lee, Jeffrey E., Kim, Michael, Katz, Matthew H.G., Tzeng, Ching-Wei D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7309587/
https://ncbi.nlm.nih.gov/pubmed/31210666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPA.0000000000001345
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados